Eilmeldung

Anthropic Faces Government Ban on Advanced AI Models Amidst Business Growth Amazon's Project Kuiper Faces Launch Bottlenecks Despite Satellite Readiness New Study Reveals Widespread Horizontal Gene Transfer in Animals Anthropic Pauses Planned Price Hikes for Claude Agent SDK Apple to Change Hide My Email Feature, Potentially Blocking Anonymous Sign-Ups Fox Corp. to Acquire Roku for $22 Billion in Strategic Pivot Iraq's World Cup Qualification Ignites Passion in Michigan's Iraqi Diaspora DOJ Approves Skydance-Paramount Warner Bros. Deal Amidst Internal Disagreement SpaceX Briefly Becomes World's 5th Most Valuable Company After IPO Surge Person in Custody in Investigation of Cross Set on Fire in Chicago Park Anthropic Faces Government Ban on Advanced AI Models Amidst Business Growth Amazon's Project Kuiper Faces Launch Bottlenecks Despite Satellite Readiness New Study Reveals Widespread Horizontal Gene Transfer in Animals Anthropic Pauses Planned Price Hikes for Claude Agent SDK Apple to Change Hide My Email Feature, Potentially Blocking Anonymous Sign-Ups Fox Corp. to Acquire Roku for $22 Billion in Strategic Pivot Iraq's World Cup Qualification Ignites Passion in Michigan's Iraqi Diaspora DOJ Approves Skydance-Paramount Warner Bros. Deal Amidst Internal Disagreement SpaceX Briefly Becomes World's 5th Most Valuable Company After IPO Surge Person in Custody in Investigation of Cross Set on Fire in Chicago Park

Big Pharma

Stabil3 Meldungen2 QuellenZuletzt aktualisiert: 14 sa önce

Verwandte ThemenIPO biotech JPMorgan healthcare M&A drug development pipeline mergers and acquisitions

Neueste Meldungen

Biotech IPO Window Reopens, But Big Pharma Acquisitions Remain Strong

Business·14 sa önceKI-Zusammenfassung

Biotech IPO Window Reopens, But Big Pharma Acquisitions Remain Strong

The biotech IPO market is showing signs of recovery, but top dealmakers at JPMorgan suggest strong companies may still opt for acquisition by Big Pharma. Investors are more selective, leading many biotechs to pursue dual-track strategies. This trend reflects a broader healthcare dealmaking rebound driven by Big Pharma's need to replenish pipelines.

Biopharma M&A Surges, Poised for Strongest Year Since 2019 Peak

Business·04.06.2026KI-Zusammenfassung

Biopharma M&A Surges, Poised for Strongest Year Since 2019 Peak

Global biopharma M&A is accelerating in 2026, driven by patent cliffs and pipeline needs. Dealmaking has reached $106 billion, on track to exceed $250 billion, the highest since 2019. Strategic 'bolt-on' acquisitions under $5 billion dominate, with a growing interest in Chinese assets.

MPs challenge Wes Streeting’s new powers over NHS drug pricing

Politik·26.04.2026KI-Zusammenfassung

MPs challenge Wes Streeting’s new powers over NHS drug pricing

Thirty-one MPs have launched a parliamentary challenge against new powers granted to Health Secretary Wes Streeting, allowing him to dictate NHS drug spending thresholds. Critics argue the move undermines the independence of Nice and favors US pharmaceutical interests.